Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery

Author(s): Francesco Marchesi and Andrea Mengarelli

Volume 23 , Issue 21 , 2016

Page: [2217 - 2229] Pages: 13

DOI: 10.2174/0929867323666160517115907

Price: $65

Abstract

To date, two kinds of Granulocyte Colony-Stimulating Factors (G-CSF) have been approved for autologous peripheral blood hematopoietic stem cell (PBSCs) mobilization and posttransplant hematologic recovery after high-dose chemotherapy: filgrastim (originator and biosimilar) and lenograstim. Biosimilar filgrastim has been approved on the basis of comparable efficacy and safety in clinical studies where it has been used as chemotherapy-induced febrile neutropenia prophylaxis, but no specific pre-registration studies have been published in the transplant setting. Hence, there is still general skepticism about the role of biosimilar G-CSFs in this setting of patients. This review of biochemical, pre-clinical and clinical data suggests significant comparability of biosimilar filgrastim with both originator filgrastim and lenograstim in autologous PBSCs mobilization and post-autograft hematologic recovery.

Keywords: Autologous stem cell transplant, Biosimilar filgrastim, Hematologic recovery, Lenograstim, Originator filgrastim, Peripheral blood hematopoietic stem cell mobilization.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy